Oncocross

Oncocross is an AI-driven drug discovery company. Oncocross primarily focuses on new drug candidates entering clinical stages or already marketed drugs with certified safety, collaborating with pharmaceutical companies in these fields. Oncocross's drug discovery platform, named RAPTOR AI, leverages an AI platform based on transcriptomic data to discover innovative therapies, new indications for existing drugs, and indications for novel drug combinations. The company’s key pipelines currently under follow-up include a sarcopenia candidate drug "OC514" and a reperfusion injury inhibitor candidate drug "OJP3101."